Edwards Lifesciences Stock (NYSE:EW)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$65.37

52W Range

$58.93 - $96.12

50D Avg

$66.38

200D Avg

$81.15

Market Cap

$39.45B

Avg Vol (3M)

$6.75M

Beta

1.13

Div Yield

-

EW Company Profile


Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

19,800

IPO Date

Mar 27, 2000

Website

EW Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Transcatheter Aortic Valve Replacement$3.88B$3.52B$3.42B
Critical Care$928.10M$855.00M$834.90M
Surgical Heart Valve Therapy$999.30M$893.10M$889.10M
Transcatheter Mitral And Tricuspid Therapies$197.60M$116.10M$86.00M

Fiscal year ends in Dec 23 | Currency in USD

EW Financial Summary


Dec 23Dec 22Dec 21
Revenue$6.00B$5.38B$5.23B
Operating Income$1.53B$1.75B$1.35B
Net Income$1.40B$1.52B$1.50B
EBITDA$1.53B$1.83B$1.48B
Basic EPS$2.31$2.46$2.41
Diluted EPS$2.30$2.44$2.38

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 24, 24 | 9:45 PM
Q1 24Apr 25, 24 | 12:00 AM
Q4 23Feb 06, 24 | 9:05 PM

Peer Comparison


TickerCompany
ZBHZimmer Biomet Holdings, Inc.
ABTAbbott Laboratories
PODDInsulet Corporation
SYKStryker Corporation
MDTMedtronic plc
DXCMDexCom, Inc.
TNDMTandem Diabetes Care, Inc.
ALGNAlign Technology, Inc.